Shots:
LAVA to receive $50M up front & is also eligible to receive ~$650M in development, regulatory & commercial milestones along with royalties. Under the terms of the agreement, Seagen will develop & commercialize LAVA-1223, a bispecific T cell engager that was designed to target & activate Vγ9Vδ2 (gamma delta) t cells in the presence of EGFR-expressing solid tumors
Seagen to get an exclusive license globally for LAVA-1223 & also has an option to nominate ~2 additional tumor targets for bispecifics by using LAVA’s Gammabody platform
The agreement enables Seagen to use its expertise along with global development & commercialization capabilities to develop targeted cancer therapies to improve the lives of patients
Ref: Seagen | Image: Seagen
